Gennova Subsidiary Sells mRNA Business via Slump Sale to Immunoscript for Rs. 1,395 Million
Emcure Pharmaceuticals Ltd's subsidiary, Gennova Biopharmaceuticals Limited, has executed a business transfer agreement regarding its mRNA division. The division was sold as a going concern on a slump sale basis to Immunoscript Life Science Private Limited.The agreement was finalized on July 10, 2026. The transaction involves the comprehensive transfer of Gennova's mRNA business to Immunoscript for a lump sum cash consideration of Rs. 1,395 Million. The completion of the slump sale is expected by July 17, 2026, pending fulfillment of necessary conditions precedent and approvals outlined in the Business Transfer Agreement (BTA).
The buyer, Immunoscript Life Science Private Limited, is a company promoted by Dr. Sanjay Singh, who was formerly a Director of Gennova. The transaction does not fall within related party transactions as of the date of execution.
A summary of the financial and operational details pertaining to the transfer are provided below:
| Metric | Value |
|---|---|
| Sale Consideration | Rs. 1,395 Million (Lump sum cash) |
| Date of Agreement | July 10, 2026 |
| Expected Completion Date | July 17, 2026 |
The mRNA business contributed specific metrics to the parent company's figures for Fiscal Year 2025-26.
| Metric (FY 2025-26) | Gennova Contribution | Percentage of Consolidated Entity Figure |
|---|---|---|
| Revenue | Rs. 647.10 Million | 0.71% of consolidated revenue (Rs. 91,158.88 Million) |
| Net Worth | Rs. 1,326.31 Million | 2.68% of consolidated net worth (Rs. 49,500.32 Million) |
Gennova's total turnover for FY 2025-26 was reported at Rs. 4,917.42 Million.
The transfer of the mRNA business is noted as part of Gennova's strategic initiative to reorganize its operations and refocus on core areas, which include research and development, manufacturing and marketing biotechnology based products such as biosimilars and adjacent therapeutic platforms.
Immunoscript Life Science Private Limited is described as having a vision to advance precision immunology through the integration of biological engineering, artificial intelligence, and scalable biomanufacturing technologies to accelerate next-generation vaccines and advanced therapeutics for precision healthcare.
EMCURE Stock Price Movement
On Friday, shares of Emcure Pharmaceuticals Limited shed 0.25% during trading, settling at ₹1814.40. The stock saw a volume of 74,788 shares traded on the day.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.